Page 123 - JSOM Summer 2023

help providers triage transport, supplies, and make difficult 19. Griffin JH, Zlokovic BV, Mosnier LO. Protein C anticoagulant and
life and death decisions. cytoprotective pathways. Int J Hematol. 2012;95(4):333–345.
20. Cauchie P, Cauchie C, Boudjeltia KZ, et al. Diagnosis and prog-
nosis of overt disseminated intravascular coagulation in a general
Disclosure hospital—meaning of the ISTH score system, fibrin monomers,
The authors have indicated they have no financial relation- and lipoprotein-C-reactive protein complex formation. Am J He-
ships relevant to this article to disclose. matol. 2006;81(6):414–419.
21. Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J
Funding Med. 2014;370(9):847–859.
None. 22. Gando S, Saitoh D, Ogura H, et al. Disseminated intravascular
coagulation (DIC) diagnosed based on the Japanese Association
for Acute Medicine criteria is a dependent continuum to overt
Author Contributions DIC in patients with sepsis. Thromb Res. 2009;123(5):715–718.
JN conceived the study concept. JL and JN wrote the first draft. 23. Shen L, Tabaie S, Ivascu N. Viscoelastic testing inside and beyond
All authors read, edited, and approved the final manuscript. the operating room. J Thorac Dis. 2017;9(Suppl 4):S299–S308.
24. Drumheller BC, Stein DM, Moore LJ, et al. Thromboelastography
References and rotational thromboelastometry for the surgical intensivist: A
1. van der Poll T, Herwald H. The coagulation system and its func- narrative review. J Trauma Acute Care Surg. 2019;86(4):710–721.
tion in early immune defense. Thromb Haemost. 2014;112(4): 25. Prakash S, Verghese S, Roxby D, et al. Changes in fibrinolysis and
640–648. severity of organ failure in sepsis: a prospective observational
2. Prentice CR. Acquired coagulation disorders. Clin Haematol. study using point-of-care test–ROTEM. J Crit Care. 2015;30(2):
1985;14(2):413–442. 264–270.
3. Østerud B, Bjørklid E. The tissue factor pathway in disseminated 26. Saha M, McDaniel JK, Zheng XL. Thrombotic thrombocytopenic
intravascular coagulation. Semin Thromb Hemost. 2001;27(6): purpura: pathogenesis, diagnosis and potential novel therapeu-
605–617. tics. J Thromb Haemost. 2017;15(10):1889–1900.
4. Delabranche X, Helms J, Meziani F. Immunohaemostasis: A new 27. Jokiranta TS. HUS and atypical HUS. Blood. 2017;129(21):
view on haemostasis during sepsis. Ann Intensive Care. 2017;7 2847–2856.
(1):117. 28. Warkentin TE. Clinical picture of heparin-induced thrombocyto-
5. Madoiwa S. Recent advances in disseminated intravascular coag- penia (HIT) and its differentiation from non-HIT thrombocyto-
ulation: endothelial cells and fibrinolysis in sepsis-induced DIC. J penia. Thromb Haemost. 2016;116(5):813–822.
Intensive Care. 2015;3:8. 29. Warkentin TE, Greinacher A, Gruel Y, et al. Laboratory testing
6. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, throm- for heparin-induced thrombocytopenia: a conceptual framework
bosis and organ dysfunction. Thromb Res. 2012;129(3):290–295. and implications for diagnosis. J Thromb Haemost. 2011;9(12):
7. Iba T, Levy JH. Inflammation and thrombosis: roles of neutro- 2498–2500.
phils, platelets and endothelial cells and their interactions in 30. Iba T, Levy JH, Wada H, Thachil J, et al. Differential diagnoses
thrombus formation during sepsis. J Thromb Haemost. 2018;16 for sepsis-induced disseminated intravascular coagulation: com-
(2):231–241. munication from the SSC of the ISTH. J Thromb Haemost. 2019;
8. Iba T, Levy JH. Derangement of the endothelial glycocalyx in sep- 17(2):415–419.
sis. J Thromb Haemost. 2019;17(2):283–294. 31. Levi M, de Jonge E, van der Poll T, ten Cate H. Advances in the
9. Bermejo-Martin JF, Martín-Fernandez M, López-Mestanza C, et understanding of the pathogenetic pathways of disseminated in-
al. Shared features of endothelial dysfunction between sepsis and travascular coagulation result in more insight in the clinical pic-
its preceding risk factors (aging and chronic disease). J Clin Med. ture and better management strategies. Semin Thromb Hemost.
2018;7(11). 2001;27(6):569–575.
10. Chappell D, Hofmann-Kiefer K, Jacob M, et al. TNF-alpha induced 32. Umemura Y, Yamakawa K, Ogura H, et al. Efficacy and safety of
shedding of the endothelial glycocalyx is prevented by hydrocor- anticoagulant therapy in three specific populations with sepsis:
tisone and antithrombin. Basic Res Cardiol. 2009;104(1):78–89. a meta-analysis of randomized controlled trials. J Thromb Hae-
11. Nelson A, Berkestedt I, Schmidtchen A, et al. Increased levels of most. 2016;14(3):518–530.
glycosaminoglycans during septic shock: relation to mortality and 33. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Cam-
the antibacterial actions of plasma. Shock. 2008;30(6):623–627. paign: International Guidelines for Management of Sepsis and
12. Lopez E, Bermejo N, Berna-Erro A, et al. Relationship between Septic Shock: 2016. Intensive Care Med. 2017;43(3):304–377.
calcium mobilization and platelet α- and δ-granule secretion. A 34. Warren BL, Eid A, Singer P, et al. Caring for the critically ill pa-
role for TRPC6 in thrombin-evoked δ-granule exocytosis. Arch tient. High-dose antithrombin III in severe sepsis: a randomized
Biochem Biophys. 2015;585:75–81. controlled trial. Jama. 2001;286(15):1869–1878.
13. Iba T, Gando S, Thachil J. Anticoagulant therapy for sepsis-as- 35. Hoffmann JN, Wiedermann CJ, Juers M, et al. Benefit/risk profile
sociated disseminated intravascular coagulation: the view from of high-dose antithrombin in patients with severe sepsis treated
Japan. J Thromb Haemost. 2014;12(7):1010–1019. with and without concomitant heparin. Thromb Haemost. 2006;
14. Levy JH, Sniecinski RM, Welsby IJ, Levi M. Antithrombin: an- 95(5):850–856.
ti-inflammatory properties and clinical applications. Thromb 36. Emleek EMQ, Khalil AA. Disseminated intravascular coagulop-
Haemost. 2016;115(4):712–728. athy in critically ill patients in Amman, Jordan. Biol Res Nurs.
15. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrom- 2021;23(4):689–697.
bin: a new look at the actions of a serine protease inhibitor. Blood 37. Bates A, Donohue A, McCullough J, Winearls J. Viscoelastic hae-
Coagul Fibrinolysis. 2002;13(8):657–670. mostatic assays in aeromedical transport. Emerg Med Australas.
16. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple 2020;32(5):786–792.
organ failure, and disseminated intravascular coagulation. Com- 38. Lantry JH, Mason P, Logsdon MG, et al. Hemorrhagic resusci-
pared patterns of antithrombin III, protein C, and protein S defi- tation guided by viscoelastography in far-forward combat and
ciencies. Chest. 1992;101(3):816–823. austere civilian environments: Goal-directed whole-blood and
17. Chappell D, Jacob M, Hofmann-Kiefer K, et al. Antithrombin re- blood-component therapy far from the trauma center. J Clin Med.
duces shedding of the endothelial glycocalyx following ischaemia/ 2022;11(2).
reperfusion. Cardiovasc Res. 2009;83(2):388–396. 39. April MD, Bridwell RE, Jones J, et al. Descriptive analysis of ca-
18. Choi Q, Hong KH, Kim JE, et al. Changes in plasma levels of sualties rapidly returned to the fight after injury: Reverse triage
natural anticoagulants in disseminated intravascular coagulation: implications for large scale combat operations. Med J (Ft Sam
high prognostic value of antithrombin and protein C in patients Houst Tex). 2022;Per 22-04-05-06(Per 22-04-05-06):3–9.
with underlying sepsis or severe infection. Ann Lab Med. 2014;34
(2):85–91. PMID: 37302145; DOI: 10.55460/6OZC-JIOV

DIC in Austere Critical Care | 121